The U.S. Food and Drug Administration has unveiled a pilot voucher program designed to expedite the review process for drugs that align with specified national health priorities. This initiative aims to reduce the standard review timeline from around 10 months to just one or two months, providing accelerated agency feedback to incentivize pharmaceutical companies. FDA Commissioner Marty Makary highlighted the move as a strategy to improve efficiency by allowing companies to submit a majority of their applications before clinical trials are fully complete. However, experts caution about the risks of political influence in voucher distribution and raise concerns about potential unintended consequences of the expedited review process.